AngelaDispenzieriMD

Hematology • Rochester, MN

Professor, Internal Medicine, Mayo Medical School

Join to view full profile

Dr. Dispenzieri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Dispenzieri's full profile

Already have an account?

Office
200 1st Street SW
Rochester, MN 55905
Is this information wrong?

Summary

Dr. Angela Dispenzieri is a hematologist in Rochester, MN and is affiliated with Mayo Clinic Hospital - Rochester. She received her medical degree from Albert Einstein College of Medicine and has been in practice 26 years. She is experienced in hematopoietic stem cell transplantation, multiple myeloma, POEMS syndrome, and mass spectrometry.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1994 - 1998
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1991 - 1994
Albert Einstein College of MedicineClass of 1991
Massachusetts Institute of TechnologyB.S., Biology, 1981 - 1985

Certifications & Licensure

MN State Medical License 1992 - 2025
American Board of Internal Medicine Hematology

Clinical Trials

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis Start of enrollment: 2001 Dec 01
Terminated
Phase 1
Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2002 Sep 01
Completed
Phase 2
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis Start of enrollment: 2005 Apr 01
Completed
Phase 2
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma Start of enrollment: 2006 Nov 30
Completed
Phase 1, Phase 2
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma Start of enrollment: 2005 May 31
Completed
Phase 1
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Sep 01
Completed
Phase 1, Phase 2
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain Start of enrollment: 2005 Mar 21
Completed
Phase 1, Phase 2
Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant Start of enrollment: 2000 Jan 01
Completed
Phase 1, Phase 2
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Start of enrollment: 2010 Nov 01
Completed
Phase 3
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome Start of enrollment: 2016 Oct 31
Active, not recruiting
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.
Saurabh Zanwar, Morie A Gertz, Eli Muchtar, Francis K Buadi, Taxiarchis Kourelis, Wilson Gonsalves, Ronald S Go, Suzanne Hayman, Prashant Kapoor, Moritz Binder, Josell...> ;Leukemia. 2024 Apr 9
AL amyloidosis response: a move in the "light" direction.
Angela Dispenzieri> ;Blood. 2024 Mar 28
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide.
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalv...> ;Blood Cancer Journal. 2024 Mar 26
Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week.
Esther Gonzalez-Lopez, Ellen D McPhail, Clara Salas-Anton, Fernando Dominguez, Morie A Gertz, Angela Dispenzieri, Surendra Dasari, Paolo Milani, Laura Verga, Martha Gr...> ;Journal of the American College of Cardiology. 2024 Mar 19
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Ghobrial, I., Gormley, N., Kumar, S., Mateos, M., Bergsagel, P., Chesi, M., Dhodapkar, M., Dispenzieri, A., Fonseca, R., Getz, G., Kastritis, E., Kristinsson, S., Mart...> ;Blood Cancer Discovery. 2024 Mar 4
Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up.
Nadine Abdallah, Thomas E Witzig, Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, Angela Dispenzieri, Vivek Roy, Morie A Gertz, P Leif Bergsagel, S Vincent Rajkumar> ;Leukemia. 2024 Feb 28
Cardiac Troponin in Patients With Light Chain and Transthyretin Cardiac Amyloidosis:State-of-the-Art Review.
Laura De Michieli, Alberto Cipriani, Sabino Iliceto, Angela Dispenzieri, Allan S Jaffe> ;JACC. Cardiooncology. 2024 Feb 1
Mode of progression in smoldering multiple myeloma: a study of 406 patients.
Abdallah, N., Lakshman, A., Kumar, S., Cook, J., Binder, M., Kapoor, P., Dispenzieri, A., Gertz, M., Lacy, M., Hayman, S., Buadi, F., Dingli, D., Lin, Y., Kourelis, T....> ;Blood Cancer Journal. 2024 Jan 17
Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Gentile, L., Diemberger, I., Plante-Bordeneuve, V., Mazzeo, A., Dori, A., Luigetti, M., Di Paolantonio, A., Dispenzieri, A., Grogan, M., Waddington Cruz, M., Adams, D....> ;Plos One. 2024 Jan 1
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno, J., Coelho, T., Tournev, I., Waddington-Cruz, M., Wixner, J., Diemberger, I., Garcia-Pavia, P., Chapman, D., Gupta, P., Glass, O., Amass, L., , Dispen...> ;Cardiology and Therapy. 2024 Mar 1
Muscle and fat composition in patients with newly diagnosed multiple myeloma.
Abdallah, N., Nagayama, H., Takahashi, N., Gonsalves, W., Fonder, A., Dispenzieri, A., Dingli, D., Buadi, F., Lacy, M., Hobbs, M., Gertz, M., Binder, M., Kapoor, P., W...> ;Blood Cancer Journal. 2023 Dec 12
1 citations
A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis.
Dasari, S., Theis, J., Vrana, J., Leung, N., Ramirez-Alvarado, M., Charalampous, C., McPhail, E., Dispenzieri, A., Muchtar, E., Gertz, M., Kourelis, T.> ;Kidney International. 2024 Mar 1
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
Charalampous, C., Goel, U., Kapoor, P., Binder, M., Buadi, F., Cook, J., Dingli, D., Dispenzieri, A., Fonder, A., Gertz, M., Gonsalves, W., Hayman, S., Hobbs, M., Hwa,...> ;Blood Cancer Journal. 2023 Dec 11
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma.
Sarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Din...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Mar 1
Identification of amyloidosis of the urinary tract and prostate: Opportunities for early diagnosis & intervention in systemic disease.
Sarwat I Gilani, Surendra Dasari, Burak Tekin, Loren Herrera Hernandez, John C Cheville, Rafael E Jimenez, Karen L Rech, Linda N Dao, Matthew T Howard, Joanna C Dallan...> ;Human Pathology. 2023 Dec 1
3 citations
A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Luca Gentile, Teresa Coelho, Angela Dispenzieri, Isabel Conceição, Márcia Waddington-Cruz, Arnt Kristen, Jonas Wixner, Igor Diemberger, Juan Gonzalez-Moreno, Eve Cario...> ;Orphanet Journal of Rare Diseases. 2023 Nov 10
Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients.
S Rajkumar, Nadine Abdallah, Arjun Lakshman, Shaji Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie Gertz, Martha Lacy, Suzanne Hayman, F...> ;Research Square. 2023 Oct 23
Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
Rivka Goldis, Batia Kaplan, Michael Arad, Angela Dispenzieri, Surendra Dasari, Olga Lesya Kukuy, Amos J Simon, Amir Dori, Efrat Shavit-Stein, Tamar Ziv, David Murray, ...> ;Clinical Chemistry and Laboratory Medicine. 2024 Feb 26
POEMS syndrome: Update on diagnosis, risk-stratification, and management.
Angela Dispenzieri> ;American Journal of Hematology. 2023 Dec 1
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Paul G Richardson, Brian G Durie, Laura Rosiñol, Maria-Victoria Mateos, Angela Dispenzieri, Philippe Moreau, Shaji Kumar, Noopur Raje, Nikhil Munshi, Jacob P Laubach, ...> ;Haematologica. 2023 Nov 1
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi, Joselle Cook, David Dingli, Angela Dispenzieri, Amie L Fonder, Morie A Gertz, ...> ;Blood Advances. 2023 Aug 22
1 citations
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma.
Walker M Schmidt, Nirosha D Perera, Francis K Buadi, Suzanne R Hayman, Shaji K Kumar, Angela Dispenzieri, David Dingli, Joselle Cook, Martha Q Lacy, Prashant Kapoor, N...> ;Blood Cancer Journal. 2023 Aug 18
1 citations
Imaging of Castleman Disease.
Marika A Pitot, Ali D Tahboub Amawi, Lauren F Alexander, Jordan D LeGout, Lara Walkoff, Patrick J Navin, Akira Kawashima, Adam J Wood, Angela Dispenzieri, Sudhakar K V...> ;Radiographics. 2023 Aug 1
2 citations
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.
Udit Yadav, Shaji K Kumar, Linda B Baughn, Angela Dispenzieri, Patricia Greipp, Rhett Ketterling, Dragan Jevremovic, Francis K Buadi, David Dingli, Martha Q Lacy, Rafa...> ;Blood. 2023 Nov 30
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay.
Teresa Coelho, Angela Dispenzieri, Martha Grogan, Isabel Conceição, Márcia Waddington-Cruz, Arnt V Kristen, Jonas Wixner, Igor Diemberger, Juan Gonzalez-Moreno, Mathew...> ;Amyloid. 2023 Dec 1
Join now to see all

Journal Articles

Systemic Amyloidosis Recognition, Prognosis, and Therapy
Morie A Gertz, Angela Dispenzieri, JAMA
Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma
S Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation
Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse
Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature
Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia
Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
Daratumumab-Based Therapy in Patients with Heavily-Pretreated AL Amyloidosis
Saurabh Zanwar, Angela Dispenzieri, Wilson Gonsalves, David Dingli, Jithma P Abeykoon, Martha Q Lacy, Shaji Kumar, Nelson Leung, Morie A Gertz, Eli Muchtar, Francis Bu..., Nature
Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy: Failure of the Serum Free Light Chain Ratio
Morie A Gertz, David Dingli, Miriam Hobbs, John A Lust, Ronald S Go, Amie Fonder, Yi Lin, Shaji K Kumar, Prashant Kapoor, Taxiarchis V Kourelis, S Vincent Rajkumar, Ro..., Nature
Comparable Outcomes Using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
Morie A Gertz, Shaji K Kumar, Martha Q Lacy, Prashant Kapoor, Suzanne R Hayman, Robert C Wolf, William J Hogan, Wilson I Gonsalves, Angela A Dispenzieri, David Dingli,..., Nature
International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease
Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...
John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
Assay to Rapidly Screen for Immunoglobulin Light Chain Glycosylation: A Potential Path to Earlier AL Diagnosis for a Subset of Patients
Angela Dispenzieri, MD, Nature
A Universal Solution for Eliminating False Positives in Myeloma Due to Therapeutic Monoclonal Antibody Interference
David L Murray, Angela Dispenzieri, Blood
Monoclonal Gammopathy of Clinical Significance: A Novel Concept with Therapeutic Implications
Robert A Kyle, Nelson Leung, Angela Dispenzieri, Blood
De Novo Multiple Myeloma after Kidney Transplantation
Safadi S, Leung N, Cosio F, Amer H, Gertz M, Rajkumar V, Hayman S, Lacy M, Dispenzieri A, Am J Kidney Dis, 5/1/2014
Clinical Epidemiology and Treatment Patterns of Patients with Multicentric Castleman Disease: Results from Two Us Treatment Centres
Robinson D Jr, Reynolds M, Casper C, Dispenzieri A , Vermeulen J, Payne K, Schramm J, Ristow K, Desrosiers MP, Yeomans K, Teltsch D, Swain R, Habermann TM, Rotella P, ..., Br J Haematol, 4/1/2014
S0120 Gems: Genomics Encounters MGUS and SMM
Dispenzieri A, Blood, 1/2/2014
Erratum: Long-term Outcome of Patients with Multiple Myeloma-related Advanced Renal Failure following Auto-SCT (Bone Marrow Transplantation (2014) 49 (996) DOI:101038/...
Glavey SV, Gertz MA, Dispenzieri A , Kumar S, Buadi F, Lacy M, Hayman SR, Kapoor P, Dingli D, McCurdy A, Hogan WJ, Gastineau DA, Leung N, Bone Marrow Transplant, 1/1/2014
A Review of Poems Syndrome
Dispenzieri A , Buadi FK, Oncology-New York, 12/1/2013
Outcomes of Pacing in Patients with Cardiac Amyloidosis - A Single Center Experience
Hai JJ, Webster TL, Lin G, Dispenzieri A , Grogan M, Brady PA, Circulation, 11/26/2013
Serum Immunoglobulin Free Light Chains and Rheumatoid Arthritis: A Population-based Study
Davis JM, Rajkumar SV, Crowson CS, Deng XL, Dispenzieri A , Larson DR, Therneau TM, Matteson EL, Kyle RA, Katzmann J, Gabriel SE, Arthritis Rheum, 10/1/2013
Prediction of Poor Mobilization of Autologous Cd34+cells in Multiple Myeloma (MM): Implications for Risk-stratification
Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A , Kramer CP, Kang Y, Gertz MA, Stuart RK, Kumar SK, Transfusion, 9/1/2013
Can Longitudinal Strain by 2 Dimensional Speckle Tracking Echocardiography Provide Diagnostic and Prognostic Value in Immunoglobulin Light Chain and Hereditary Transth...
Xu YL, Dispenzieri A , Pellikka PA, Olson M, Cha S, Villarraga HR, Eur Heart J, 8/1/2013
Use of Cmri for Prognosis of Cardiac Amyloidosis
Boynton S, Dispenzieri A , Syed I, Grogan M, Araoz P, Glockner J, J Am Coll Cardiol, 3/12/2013
Electrocardiographic Findings in Transthyretin-related Cardiac Amyloidosis
O'Donnell E, Klarich K, Olson A, Lin G, Brady P, Dispenzieri A , Gertz M, Zeldenrust S, Grogan M, J Am Coll Cardiol, 3/12/2013
Sensitivity of Subcutaneous Fat Aspirate Biopsy for Detection of Systemic Amyloidosis in Cardiac Biopsy-proven Transthyretin Cardiomyopathy
Fine NM, Olson A, Zeldenrust S, Miller F, Bielinski S, Klarich K, Dispenzieri A , Scott C, Grogan M, J Am Coll Cardiol, 3/12/2013
Join now to see all

Books/Book Chapters

Multiple Myeloma: Diagnosed and Treatment
Chapter: POEMS Syndrome (Takatsuki Syndrome)
Page 179 - 193Dispenzieri AEditors: Gertz MA; Rajkumar SV.Springer, New York2014
Abeloff's Clinical Oncology
Chapter: Multiple Myeloma and Related Disorders
Page 1991 - 2017Rajkumar SV, Dispenzieri AEditors: Niederhuber JE; et al.Churchill Livingstone, PhiladelphiaEdition Fift,2014
Wintrobe's Clinical Hematology
Chapter: Multiple Myeloma
Page 2046 - 2097Dispenzieri A , Lacy MQ, Kumar SEditors: Greer JP; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition Thir,2014
Wintrobe's Clinical Hematology
Chapter: Immunoglobulin Light-chain Amyloidosis (Primary Amyloidosis)
Page 2098 - 2123Gertz MA, Lacy MQ, Dispenzieri A , Zeldenrust SREditors: Greer JP; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition Thir,2014
Wintrobe's Clinical Hematology
Chapter: POEMS Syndrome, Cryoglobulinemia, and Heavy-chain Disease
Page 2141 - 2157Dispenzieri A , Dingli D, Gertz MAEditors: Greer JP; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition Thir,2014
Myeloma-Pathology, Diagnosis, and Treatment
Chapter: POEMS Syndrome and Paraproteinemic Syndromes: Management and Follow-up
Page 225 - 243Dispenzieri A , Hayman SEditors: Schey SA, Yong KL, Marcus R, Anderson KC.Cambridge University Press, New YorkEdition 1st,2014
Neoplastic Diseases of the Blood
Chapter: Immunoglobulins and Laboratory Recognition of Monoclonal Proteins
Page 565 - 588Katzmann J, Kyle RA, Lust J, Snyder M, Dispenzieri AEditors: Wiernik PH; et al.Springer, New YorkEdition 5th,2013
Clinical Immunology: Principles and Practice
Chapter: Monoclonal Gammopathies
Page 975 - 986Kyle RA, Dispenzieri AEditors: Rich RR; et al.Elsevier/Saunders, OxfordEdition 4th,2013
Non-Hodgkin Lymphomas
Chapter: Diagnosis and Management of Disorders That Can Mimic Lymphoma
Page 557 - 585Dispenzieri A , Pittaluga S, Facchetti F, Feuillard J, Jaffe ESEditors: Armitage JO; et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition 2nd,2010
Amyloidosis: Diagnosis and Treatment
Chapter: Assessing Response and Prognosis in AL Amyloidosis
Page 77 - 93Dispenzieri AEditors: Gertz MA; Rajkumar SV.Humana Press, New York2010
Protein Misfolding Diseases: Current and Emerging Principles and Therapies
Chapter: Current Therapies for Light-chain Amyloidosis
Page 775 - 793Dispenzieri A , Kumar SEditors: Ramirez-Alvarado M; Kelly JW; Dobson CM.Wiley, Hoboken2010
Non-Hodgkin Lymphomas
Chapter: Chapter 38: Diagnosis and Management of Disorders that Can Mimic Lymphoma
Dispenzieri A , Pittaluga S, Facchetti F, Feuillard J, Jaffe EEdition Seco,2009
Myeloma Therapy: Pursuing the Plasma Cell
Chapter: Chapter 34: POEMS Syndrome and Other Atypical Plasma Cell Disorders
Dispenzieri ASpringer2009
Hematology: Basic Principles and Practice
Chapter: Immunoglobulin Light-chain Amyloidosis (Primary Amyloidosis)
Page 1425 - 1447Gertz MA, Lacy MQ, Dispenzieri A , Hayman SREditors: Hoffman R, et al.Churchill Livingstone/Elsevier, PhiladelphiaEdition 5th,2009
Treatment of Multiple Myeloma and Related Disorders
Chapter: Diagnosis and Treatment of POEMS Syndrome
Page 182 - 194Dispenzieri AEditors: Rajkumar SV, Kyle RA.Cambridge University Press, Cambridge; New York2009
Wintrobe's Clinical Hematology
Chapter: Cryoglobulinemia and Heavy Chain Disease
Page 2484 - 2496Dispenzieri A , Gertz MA, Witzig TEEditors: Greer JP, et al.Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaEdition 12th,2009
Encyclopedia of Molecular Mechanisms of Disease
Chapter: POEMS Syndrome
Dispenzieri A2008
Myeloma Therapy: Pursuing the Plasma Cell
Chapter: POEMS Syndrome and Other Atypical Plasma Cell Disorders
Page 571 - 623Dispenzieri AEditors: Lonial S.Humana, Totowa2008
Textbook of Cardiovascular Medicine
Chapter: Hematologic Disorders and the Heart
Page 604 - 612Tefferi A, Dispenzieri AEditors: Topol EJ.Lippincott Williams & Wilkins, PhiladelphiaEdition 3rd,2007
Clinical Malignant Hematology
Chapter: Definition of Remission, Prognosis, and Follow-up
Page 913 - 926Rajkumar SV, Dispenzieri AEditors: Sekeres MA, Kalaycio ME, Bolwell BJ.McGraw-Hill Medical, New York2007
Neurological Therapeutics: Principles and Practice
Chapter: Neuropathy Associated with the Monoclonal Gammopathies
Page 2401 - 2414Kyle RA, Dispenzieri AEditors: Noseworthy JH.Informa Healthcare, AbingdonEdition 2nd,2006
Neurological Therapeutics: Principles and Practice
Chapter: Amyloidosis
Page 2415 - 2425Kyle RA, Dispenzieri AEditors: Noseworthy JH.Informa Healthcare, AbingdonEdition 2nd,2006
Hematology: Basic Principles and Practice
Chapter: Amyloidosis
Page 1537 - 1560Gertz MA, Lacy MQ, Dispenzieri AEditors: Hoffman R, et al.Elsevier Churchill Livingstone, PhiladelphiaEdition 4th,2005
Peripheral Neuropathy
Chapter: POEMS Syndrome (Osteosclerotic Myeloma)
Page 2453 - 2469Dispenzieri A , Suarez GA, Kyle RAEditors: Dyck PJ, Thomas PK.Elsevier Saunders, PhiladelphiaEdition 4th,2005
Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders
Chapter: Immunoglobulin Light Chain Amyloidosis (Primary Amyloidosis, AL)
Page 157 - 195Gertz MA, Lacy MQ, Dispenzieri AEditors: Gertz MA, Greipp PR.Springer, Berlin2004
Join now to see all

Abstracts/Posters

Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Proteomic Atlas of Cardiac Amyloidosis
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis
Angela Dispenzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma
2013 BMT Tandem Meetings, Salt Lake City, Utah, 2/1/2013
Redefining Engraftment Syndrome: The New Mayo Clinic Criteria
2013 BMT Tandem Meetings, Salt Lake City, Utah, 2/1/2013
POEMS Syndrome: More than a Medical Verse
Henry Ford Hospital Medical Grand Rounds, 5/1/2011
Update on Amyloidosis
3rd Annual Canadian Conference on LPD, 3/1/2011
A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone in Patients with Early Stage Multiple Myeloma
Witzig TE, Mandrekar S, Detweiler-Short K, Lacy MQ, Laumann K, Dispenzieri A , Hayman SR, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Rajkumar SV, Blood (ASH Annual Meeting Abstracts), 11/1/2010
Join now to see all

Lectures

Monoclonal Gammopathies of Cutaneous, Neuropathic, and Renal Significance
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM).
2019 ASCO Annual Meeting - 6/1/2019
Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome.
2019 ASCO Annual Meeting - 6/1/2019
Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long-Term Survivorship with Active Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
POEMS Syndrome, 2014 and Beyond
Hong Kong, China - 9/1/2014
Current Definition of Asymptomatic Myeloma
Milan, Italy - 6/1/2014
POEMS Syndrome: A Case Based Approach to Evaluation and Best Management
Chicago, Illinois - 6/1/2014
Measles Oncolytic Therapy
Boston, Massachusetts - 4/1/2014
Benign Monoclonal Gammopathy: How Benign Is It Really? How Do We Know It?
Austin Court, Birmingham, United Kingdom - 3/1/2014
Plasma Cell Clones - When to Worry. A Multidisciplinary Approach
Manchester, United Kingdom - 3/1/2014
Novel Agents for Myeloma - A 2014 Update
Manchester, United Kingdom - 3/1/2014
Amyloidosis: Should Our Treatment Approches Be More Personalized? When is High-Dose Chemotherapy the Best Choice
Grapevine, Texas - 2/1/2014
Initial Therapy for Multiple Myeloma
Scottsdale, Arizona - 1/1/2014
Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib
New Orleans, Louisiana - 12/1/2013
Effect Of Immedicate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma
New Orleans, Louisiana - 12/1/2013
POEMS
Cesme, Turkey - 10/1/2013
Management of Newly Diagnosed Multiple Myeloma
Cesme, Turkey - 10/1/2013
ABMT/Tandrem Transplant in the Era of New Drugs
Cesme, Turkey - 10/1/2013
Allo Transplantation in Multiple Myeloma
Cesme, Turkey - 10/1/2013
AL Amyloidosis and Light-Chain Deposition Disease
Houston, Texas - 9/1/2013
Join now to see all

Other

Primary Amyloidosis
European School of Oncology Website
8/1/2013
Treatment Paradigms of Multiple Myeloma: Do Emerging Therapies Offer an Advantage
Live CME Certified, Satellite Broadcast
Chicago, Illinois - 9/1/2006
Multiple Myeloma Module
Dispenzieri A, PIER for the ACP
1/1/2003

Authored Content

Systemic Amyloidosis Recognition, Prognosis, and TherapyJuly 2020
Systemic Amyloidosis Recognition, Prognosis, and TherapyJuly 2020

Press Mentions

Mayo Clinic Research in the News — 8/9/2021August 10th, 2021
Predictors of Short-Term Survival in Waldenström MacroglobulinemiaJuly 14th, 2020
Takeda Provides Update on TOURMALINE-MM2 Phase 3 TrialMarch 10th, 2020
Join now to see all